YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$13.73 USD
-0.27 (-1.93%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $13.71 -0.02 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 1 - 20 ( 154 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Miss; 1Q24 Financials Reported; Raising PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Factoring in Revenue from SADA Assets; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for YMAB 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Y-mAbs Looking for SADA to Make a Happy New Year
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New CEO Appointed; CD38-SADA Cleared to Enter Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pulling a U-Turn on YMAB; Upgrading to OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D